123696澳门论坛

Genor Biopharma (Stock code: 6998.HK) announced today that the company has submitted a clinical trial application to the Bellberry HREC Ethics Committee in Australia on December 20 for the first-in-human (FIH) clinical trial of GB263T, a novel EGFR/cMET/cMET trispecific therapeutic antibody, in patients with advanced malignant tumors.

Shanghai Pudong New Area Intellectual Property Office issued the "Announcement of Special Funds for the Intellectual Property Operation Service System of Pudong New Area in 2021" to reward enterprises with an outstanding performance in intellectual property management capacity building. Genor Biopharma was one of the 12 outstanding enterprises in Shanghai’s Pudong New Area that received this award.

The 2021 BioSeedin Annual Meeting & 3rd Biopharma Developer Innovation Conference were held in Shanghai from November 23-24, 2021. Dr. ZHOU Xinhua, Founder and President, and Mr. LIN Jun, Vice President of Genor Biopharma, attended the conference and the "Production and quality control of BsAb" sub-forum as chairman and guest speaker.

On November 23, 2021, Genor Biopharma received the Outstanding Employer of the Year 2021 award from Liepin.

The first Chinese Lymphoma Patients Conference was held on the occasion of the 10th anniversary of the creation of House086.com. Lymphoma patients and their families, as well as medical experts focusing on the treatment of lymphoma disease, and a number of pharmaceutical companies, including Genor Biopharma, were invited to participate in the comprehensive communication platform.